Fixed-duration therapy in leprosy: Limitations and opportunities

Indian Journal of Dermatology

Volumn 58, Issue 2, 2013, Pages 93-100

  Malathi, Munisamy ^a   Thappa, Devinder Mohan ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Fixed duration; leprosy; multibacillary; multidrug therapy; paucibacillary

Indexed keywords

CLOFAZIMINE; DAPSONE; MINOCYCLINE; OFLOXACIN; RIFAMPICIN;

DRUG COMBINATION; DRUG THERAPY; FIXED DURATION THERAPY; HISTORY OF MEDICINE; HUMAN; INDIA; LEPROSY; MULTIPLE CYCLE TREATMENT; REVIEW;

EID: 84875753858     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.108029     Document Type: Review

References (48)

1. WHO. Leprosy today. Available from: http://www.who.int/lep/en/. [Last assessed on 2012 Aug 05].
2. India's alarming share of global new leprosy cases. Available from: http://www.thehindu.com/sci-tech/science/article2995018.ece. [Last assessed on 2012 Aug 05].
3. Desikan KV. Elimination of leprosy and possibility of eradication: The Indian scenario. Indian J Med Res 2012;135:3-5.
4. Daumerie D. Implementation of MDT-Successive steps. In: Sansarricq H, editor. Multidrug therapy against leprosy: Development and implementation over the past 25 years. Geneva: WHO Library Cataloguing-in-Publication Data; 2004. p. 45-57.
5. WHO Study Group. Chemotherapy of leprosy. WHO Technical Report Series no. 847. Geneva: World Health Organization; 1994.
6. Sansarricq H. The Study Group. In: Sansarricq H, editor. Multidrug therapy against leprosy: Development and implementation over the past 25 years. Geneva: WHO Library Cataloguing-in-Publication Data; 2004. p. 45-57.
7. Jopling WH, McDougall AC. Handbook of leprosy, 5 th ed. New Delhi: CBS Publishers and Distributors; 1996. p. 101-17.
8. Dharmendra. Classifications of leprosy. In: Hastings RC, Opromolla DVA, editors. Leprosy, 2 nd ed. Edinburgh: Churchill Livingstone; 1994. p. 179-90.
9. Jacobson RR. Treatment of leprosy. In: Hastings RC, Opromolla DV, editors. Leprosy, 2 nd ed. Edinburgh: Churchill Livingstone; 1994. p. 317-49.
10. Rao CK. Implementation of WHO MDT in India 1982-2001. In: Sansarricq H, editor. Multidrug therapy against leprosy: Development and implementation over the past 25 years. Geneva: WHO Library Cataloguing-in-Publication Data; 2004. p. 92-105.
11. Pai VV, Ganapathi R, Rao R. Development and evolution of WHO MDT and newer treatment regimens. In: Kar HK, Kumar B, editors. IAL textbook of leprosy. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd.; 2010. p. 353-67.
12. Mishra RS, Kumar J. Classification. In: Kar HK, Kumar B, editors. IAL textbook of leprosy. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd.; 2010. p. 144-51.
13. WHO recommended MDT regimens. Available from: http://www.who.int/lep/mdt/ regimens/en/index.html. [Last assessed on 2012 Aug 05].
14. Worobec SM. Treatment of leprosy/Hansen's disease in the early 21 st century. Dermatol Ther 2009;22:518-37.
15. MDT: Duration of treatment FAQ. Available from: http://www.who.int/lep/ mdt/duration/en/inde×2.html. [Last assessed on 2012 Aug 05].
16. Ji B. Why multidrug therapy for multibacillary leprosy can be shortened to 12 months. Lepr Rev 1998;69:106-9.
17. Shaw IN, Christian M, Jesudasan K, Kurian N, Rao GS. Effectiveness of multidrug therapy in multibacillary leprosy: A long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity. Lepr Rev 2003;74:141-7.
18. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: Effect of length of therapy. Lepr Rev 2000;71:144-53.
19. Pönnighaus JM, Boerrigter G. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi. Int J Lepr Other Mycobact Dis 1995;63:1-7.
20. Sales AM, Sabroza PC, Nery JA, Dupprè NC, Sarno EN. No difference in leprosy treatment outcomes comparing 12-and 24-dose multidrug regimens: A preliminary study. Cad Saude Publica 2007;23:815-22.
21. Shetty VP, Wakade AV, Ghate SD, Pai VV, Ganapati RR, Antia NH. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT. Lepr Rev 2005;76:241-52.
22. Pattyn SR, Bourland J, Grillone S, Groenen G, Ghys P. Combined regimens of one year duration in the treatment of multibacillary leprosy-Combined regimens with rifampicin administered during one year. Lepr Rev 1989;60:109-17.
23. Pattyn SR. Efficacy of different regimens in multibacillary leprosy. Lepr Rev 1986;57:265-71.
24. Pai VV. Chemotherapy of leprosy-further challenges. Available from: http://medind.nic.in/haa/t06/i2/haat06i2p72.pdf. [Last assessed on 2012 Aug 05].
25. Girdhar BK, Girdhar A. Short course treatment of leprosy: Present status. Available from: http://icmr.nic.in/bufeb02.pdf. [Last assessed on 2012 Aug 05].
26. Anonymous. Persisting Mycobacterium leprae among THELEP trial patients in Bamako and Chingleput. Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) Scientific Working Group of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Lepr Rev 1987;58:325-37.
27. Sharma A, Sharma VK, Rajwanshi A, Das A, Kaur I, Kumar B. Presence of M. leprae in tissues in slit skin smear negative multibacillary (MB) patients after WHO-MBR. Lepr Rev 1999;70:281-6.
28. Lemaster JW, Shwe T, Butlin CR, Roche PW. Prediction of 'highly skin smear positive' cases among MB leprosy patients using clinical parameters. Lepr Rev 2001;72:23-8.
29. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: Effect of length of therapy. Lepr Rev 2000;71:144-53.
30. Jamet P, Ji B. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis 1995;63:195-201.
31. Prasad PV, Babu A, Kaviarasan PK, Viswanathan P, Tippoo R. MDT-MB therapy in paucibacillary leprosy: A clinicopathological assessment. Indian J Dermatol Venereol Leprol 2005;71:242-5.
32. Leprosy elimination: MDT: Duration of treatment FAQ. Available from: http://www.who.int/lep/mdt/duration/en/inde×1.html. [Last assessed on 2012 Aug 05].
33. Sehgal VN, Sardana K. Immunoprophylaxis of leprosy: Current status and future prospects. Indian J Dermatol Venereol Leprol 2007;73:71-2.
34. Katoch K, Katoch VM, Natarajan M, Gupta UD, Sharma VD, Singh HB. Long term follow-up results of 1 year MDT in MB leprosy patients treated with standard MDT+once a month Minocycline and Ofloxacin. Indian J Lepr 2008;80:331-44.
35. Villahermosa LG, Fajardo TT Jr, Abalos RM, Cellona RV, Balagon MV, Dela Cruz EC, et al. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. Am J Trop Med Hyg. 2004;70:197-200.
36. Rao PN, Pratap D, Ramana Reddy AV, Sujai S. Evaluation of leprosy patients with 1 to 5 skin lesions with relevance to their grouping into paucibacillary or multibacillary disease. Indian J Dermatol Venereol Leprol 2006;72:207-10
37. Prasad P, Kaviarasan PK. Leprosy therapy, past and present: Can we hope to eliminate it? Indian J Dermatol 2010;55:316-24.
38. Bandit C. Recent Advances in Leprosy Chemotherapy. J Trop Med Parasitol 2006;29:68-76.
39. Ji B. Chemotherapy and chemoprophylaxis of leprosy. Available from: http://www.tropika.net/review/020226-Leprosy-Chemotherapy/article.pdf. [Last assessed on 2012 Aug 05].
40. Ji B, Grosset J. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev 2000;71:S81-7.
41. Report of the ninth meeting of the WHO technical advisory group on leprosy control. World Health Organization, Regional Office for South-East Asia, 2008.
42. WHO Expert Committee on Leprosy. WHO Technical Report Series 968, 2012.
43. LEPROSY-NEW DRUG REGIMENS. Available from: http://www.who.int/tdr/ research/progress/9900/methods-treatment/en/inde×5.html. [Last accessed on 2012 Aug 05].
44. Pattyn S, Grillone S. Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy. Lepr Rev 2002;73:245-7.
45. Katoch K, Katoch VM, Natrajan M, Sharma VD, Singh HB, Gupta UD. Chemotherapy trials in MB leprosy using conventional and newer drugs pefloxacin and minocycline. Indian J Dermatol Venereol Leprol 2000;66:18-25.
46. Tejasvi T, Khaitan BK, Khanna N, Pandhi RK, Singh MK. Evaluation of a new fixed duration (12 weeks) multi-drug regimen of bactericidal drugs in multibacillary leprosy. Indian J Lepr 2006;78:329-37.
47. Ji B. Accompanied MDT (AMDT)-more questions than answers. Lepr Rev 2002;73:301-7.
48. Ji B, Saunderson P. Uniform MDT (U-MDT) regimen for all leprosy patients-another example of wishful thinking. Lepr Rev 2003;74:2-6.